Development of an Expression Vector Engineering Strategy Based on tDNA Insulator Element for the Stable Expression of Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein-Reference-Cited by-同舟云学术

Development of an Expression Vector Engineering Strategy Based on tDNA Insulator Element for the Stable Expression of Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein

Published:2023-08-01 Issue:4 Volume:42 Page:140-144
ISSN:2167-9436
Container-title:Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
language:en
Short-container-title:Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Author:

Rahimpour Azam¹²,Mosallaei Meysam³,Pourghazi Farzad⁴,Tabatabaee Sayed Hassan⁵,Hoseinpoor Reyhaneh⁶,Pourmaleki Es'hagh¹²,Soosanabadi Mohsen⁷⁸

Affiliation:

1. Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3. Personalized Medicine and Genometabolomics Research Center, Hope Generation Foundation, Tehran, Iran.

4. Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

5. Department of Life Science Engineering, Faculty of New Sciences and Technology, University of Tehran, Tehran, Iran.

6. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

7. Department of Medical Genetics, Semnan University of Medical Sciences, Semnan, Iran.

8. Department of Genetics, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.

Publisher

Mary Ann Liebert Inc

Subject

Immunology,Immunology and Allergy

Link

https://www.liebertpub.com/doi/pdf/10.1089/mab.2023.0006

Reference25 articles.

1. Recent advances in CHO cell line development for recombinant protein production

2. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?

3. Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

4. Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats

5. Production of a novel heterodimeric two-chain insulin-Fc fusion protein